Τόμος 27 (2009) – Τεύχος 1 – Άρθρο 11 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 27 (2009) – Issue 1– Article 11 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Από | | Άρθρο - Article, Ελεάννα Καρά,Eleanna Kara, Παρασκευή Παπαϊωαννίδου - Paraskevi Papaioannidou, Πλήρες Κείμενο στα Ελληνικά - Full Text in Greek
Τίτλος – Title

Ογκοκατασταλτικό Γονίδιο p53: Προοπτικές Εφαρμογής στη Γονιδιακή Θεραπεία του Καρκίνου

Tumor Suppressor p53 Gene: Perspectives of Gene Therapy for Cancer
Συγγραφέας – Author

Ελεάννα Καρά, Παρασκευή Παπαϊωαννίδου

Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη, Ελλάς

Eleanna Kara, Paraskeui Papaioannidou

Department of Pharmacology, Faculty of Medicine, Aristotle University, Thessaloniki, Hellas
Παραπομπή – Citation
 Καρά,Ε., Παπαϊωαννίδου,Π. : Ογκοκατασταλτικό Γονίδιο p53: Προοπτικές Εφαρμογής στη Γονιδιακή Θεραπεία του Καρκίνου, Επιθεώρηση Κλιν. Φαρμακολ. Φαρμακοκινητ. 27: 36-39 (2009)

Kara,E., Papaioannidou,P. : Tumor Suppressor p53 Gene: Perspectives of Gene Therapy for Cancer, Epitheorese Klin. Farmakol. Farmakokinet. 27: 36-39 (2009)
Ημερομηνία Δημοσιευσης – Publication Date
8 Μαρτίου 2009 – 2009-03-08
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
Ηλεκτρονική Μορφή: pdf (15 €) –
Digital Type: pdf (15 €)
pharmakonpress[at]pharmakonpress[.]gr
Λέξεις κλειδιά – Keywords
–
Cancer, p53, gene therapy, viral delivery systems, non-viral delivery systems
Λοιποί Όροι – Other Terms

Άρθρο

Article
Περίληψη – Summary

–

Over the recent years, p53 gene therapy of cancer has undergone significant progress. Restoration of the function of the abnormal p53 gene can be accomplished by inserting the normal gene into the cancer cells via viral and non-viral vectors. The most common viral vectors are retroviruses and adenoviruses. Retroviral mediated p53 transportation is ineffective, and presents significant restrictions; however its potential use in treatment of lung cancer is under research. On the other hand, adenoviral mediated transportation is highly effective and safe but may cause host immune response, impairing thus future readministration of the recombinant virus. Adenoviral mediated p53 transportation can be used in the treatment of head and neck cancer, colon cancer, liver cancer and bladder cancer, and may also enhance the effect of cis-platine by activating the p53/p14ARF pathway. Non-viral vectors of p53 are naked plasmid DNA and cationic lipid-DNA complexes. Naked plasmid DNA has been tested in the treatment of ovarian and lung cancer, while cationic lipid-DNA complexes have been tested in radiation resistant squamous cell carcinoma, osteosarcoma, lung cancer and ovarian cancer. Attachment of transferine or antibody molecules on the surface of the p53-liposome complex increases its delivery. Moreover, gene therapy can target proteins that act as p53 activators such as Bax, p21 and MIC-1, or can transform the endogenous cancer cell p53 gene, so as to increase its resistance towards inactivating agents, like Mdm2 protein.
Αναφορές – References
 1. Gallagher W.M., Brown R.: p53-Oriented cancer therapies: Current progress. Ann. Oncol. 10: 139-150 (1999)

2. Frank D., Frederick M., Liu T., Clayman G.: Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin. Cancer Res. 4: 2521-2528 (1998)

3. Cai D.W., Mukhopadhyay T., Liu Y., Fujiwara T., Roth J.A.: Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirusmediated gene transfer. Hum. Gene Ther. 4: 617-624 (1993)

4. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A.: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86: 1458-1462 (1994)

5. Roth J.A., Cristiano R.J.: Gene therapy for cancer: What have we done and where are we going? J. Natl. Cancer Inst. 89: 21-39 (1997)

6. Herrmann F.: Cancer gene therapy: principles, problems, and perspectives. J. Mol. Med. 73: 157-163 (1995)

7. Engelhardt J.F., Ye X., Doranz B., Wilson J.M.: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. 91: 6196-6200 (1994)

8. Hong M., Lai M.D., Lin Y.S., Lai M.Z.: Antagonism of p53-dependent apoptosis by mitogen signals. Cancer Res. 59: 2847-1852 (1999)

9. Haghighi A., Lebedeva S., and Gjerset R.A.: Preferential platination of an activated cellular promoter by cis-diamminedichloroplatinum. Biochemistry 38: 12432-12438 (1999)

10. Υοο G.H., Piechocki M.P., Oliver J., Lonardo F., Zumstein L., Lin H.-S., Kim H., Shibuya T.Y, Shehadeh N., Ensley J.F.: Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 114: 1871-1879 (2004)

11. Phelan A., Elliott G., Ohare P. Intercellular delivery of functional p53 by the herpesvirus protein vp22. Nature Biotech. 16: 440-443 (1998)

12. Komiya Τ., Hirashima Τ., Kawase Ι.: Clinical significance of p53 in non-small-cell lung cancer. Oncol. Rep. 6: 19-28 (2000)

13. Collinet P., Vereecque R., Sabban F., Vinatier D., Leblanc E., Narducci F., Querleu D., Quesnel B.: In vivo
expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. J. Obstet. Gynaecol. Res. 32: 449-453 (2006)

14. Xu L., Pirollo K.F., Chang EH.: Transferrin-liposomemediated p53 sensitisation of squamous cell carcinoma of the head and neck to radiation in vitro. Hum. Gene Ther. 8: 467-475 (1997)

15. Minoru N., Madoka I., Kenya O., Takahiko K., Shinnosuke N., Toshiro T.: p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 4: 625-631 (2005)

16. Chong-Kook K., Eun-Jeong C., Sung-Hee C., Jeong-Sook P., Khawaja Hasnain H., Woong Shick A.: Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC. Gynecol. Oncol. 90: 265-272 (2003)

17. Shunsuke K., Jian G., Stephen G.S., Lin J., Jack A.R., Dejian L., Clifton S., Bingliang F.: Antitumor Effect of Adenovirus-mediated Bax Gene Transfer on p53-sensitive and p53-resistant Cancer Lines. Cancer Res. 60: 1157–1161 (2000)

18. Hong Y., Zoran F., David B., Samuel N. B., Lyubomir T. V.: Macrophage inhibitory cytokine-1: A novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2: 1023-9 (2003)

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ – ANNUAL SUBSCRIPTION
Γλώσσα Πλήρους Κειμένου –
Full Text Language
Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
pharmakonpress[at]pharmakonpress[.]gr
pharmakonpress[at]pharmakonpress[.]gr
Προσθέστε στους σελιδοδείκτες το μόνιμο σύνδεσμο.

Τα σχόλια είναι απενεργοποιημένα.